MedTrace Logo

To Evaluate the Dose Response of 3 Doses of Euphorbia Prostrata in Patients With First and Second Degree Hemorrhoids

NCT01041911 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2012-12-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safe and efficacious dose of Euphorbia prostrata for control of per rectal bleeding in patients with first and second degree hemorrhoids.

Conditions

Interventions

DRUG

Euphorbia tablets

50 mg, tablet, once daily, 14 days

DRUG

Euphorbia tablets

100 mg, tablet, once daily, 14 days

DRUG

Euphorbia tablets

200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days

DRUG

Placebo tablets

placebo, tablet, once daily, 14 days

Sponsors & Collaborators

  • Panacea Biotec Ltd

    lead INDUSTRY

Principal Investigators

  • Dr P N Agarwal · Maulana Azad Medical College, New Delhi

  • Dr Girish Bakshi · Grant Medical College, Mumbai

  • Dr T Durganna · Bangalore Medical College, Bangalore

  • Dr Saiprasad Donga · Sahil Hospital, Tawdw Niwas, 1st Floor Khopat, Thane

  • Dr Vaibhav Lokhande · Nath Hospital, Golden Heaven Society, Opp Janta Sahakari Bank, Khopat, Thane

  • Dr P S Sarangi · Deen Dayal Upadhyay Hospital, Hari Nagar, New Delhi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-10-31
Completion
2010-11-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01041911 on ClinicalTrials.gov